Jun Luo

List of Publications by Year
in descending order

105 papers	10,791 citations	66343 42 h-index	39675 94 g-index
110 all docs	110 docs citations	110 times ranked	10423 citing authors

#	Article	IF	Citations
1	AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. New England Journal of Medicine, 2014, 371, 1028-1038.	27.0	2,233
2	Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer. Cancer Research, 2009, 69, 16-22.	0.9	939
3	Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nature Medicine, 2009, 15, 559-565.	30.7	596
4	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2015, 1, 582.	7.1	552
5	Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer. Cancer Research, 2012, 72, 3457-3462.	0.9	518
6	Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Research, 2002, 62, 2220-6.	0.9	384
7	Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. Journal of Clinical Oncology, 2017, 35, 2149-2156.	1.6	371
8	Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Modern Pathology, 2008, 21, 1156-1167.	5.5	363
9	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of Clinical Oncology, 2019, 37, 1120-1129.	1.6	267
10	Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. Journal of Clinical Investigation, 2018, 129, 192-208.	8.2	266
11	DNA Methylation Alterations Exhibit Intraindividual Stability and Interindividual Heterogeneity in Prostate Cancer Metastases. Science Translational Medicine, 2013, 5, 169ra10.	12.4	231
12	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. Science Translational Medicine, 2015, 7, 269ra2.	12.4	205
13	A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate, 2011, 71, 1656-1667.	2.3	177
14	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncology, The, 2018, 19, 76-86.	10.7	149
15	Alternative splicing in prostate cancer. Nature Reviews Clinical Oncology, 2018, 15, 663-675.	27.6	142
16	Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. European Urology, 2018, 74, 218-225.	1.9	140
17	A Novel Role of Myosin VI in Human Prostate Cancer. American Journal of Pathology, 2006, 169, 1843-1854.	3.8	133
18	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget, 2018, 9, 28561-28571.	1.8	129

#	Article	IF	Citations
19	Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6810-6815.	7.1	120
20	Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate, 2002, 51, 189-200.	2.3	119
21	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. American Journal of Pathology, 2018, 188, 1478-1485.	3.8	119
22	Decoding the androgen receptor splice variants. Translational Andrology and Urology, 2013, 2, 178-186.	1.4	115
23	Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma. Prostate, 2003, 57, 134-139.	2.3	111
24	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 2018, 73, 715-723.	1.9	105
25	Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 Â® to Suppress Enzalutamide-resistant Prostate Cancer Progression. European Urology, 2017, 72, 835-844.	1.9	103
26	Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone. Hormones and Cancer, 2014, 5, 265-273.	4.9	102
27	PROSTATE CANCER DETECTION ON URINALYSIS FOR Î± METHYLACYL COENZYME A RACEMASE PROTEIN. Journal of Urology, 2004, 172, 1501-1503.	0.4	97
28	Definition of a FoxA1 Cistrome That Is Crucial for G1 to S-Phase Cell-Cycle Transit in Castration-Resistant Prostate Cancer. Cancer Research, 2011, 71, 6738-6748.	0.9	87
29	Trefoil factor 3 overexpression in prostatic carcinoma: Prognostic importance using tissue microarrays. Prostate, 2004, 61, 215-227.	2.3	85
30	Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening. Oncotarget, 2016, 7, 72593-72607.	1.8	71
31	GOLPH2 and MYO6: Putative prostate cancer markers localized to the Golgi apparatus. Prostate, 2008, 68, 1387-1395.	2.3	69
32	Supraphysiological androgens suppress prostate cancer growth through androgen receptorâ€“mediated DNA damage. Journal of Clinical Investigation, 2019, 129, 4245-4260.	8.2	67
33	Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 76, 676-685.	1.9	62
34	Expression of cancer/testis antigens in prostate cancer is associated with disease progression. Prostate, 2010, 70, 1778-1787.	2.3	60
35	Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. Oncologist, 2016, 21, 1427-1435.	3.7	60
36	Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene, 2020, 39, 6935-6949.	5.9	60

#	Article	IF	Citations
37	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clinical Cancer Research, 2015, 21, 5619-5629.	7.0	56
38	Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. European Urology, 2018, 73, 727-735.	1.9	55
39	Approaches to urinary detection of prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 362-381.	3.9	52
40	SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression. Cancer Research, 2019, 79, 5204-5217.	0.9	51
41	A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. Nature Cancer, 2020, 1, 1082-1096.	13.2	49
42	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. European Urology, 2021, 79, 692-699.	1.9	49
43	Looking Beyond Morphology: Cancer Gene Expression Profiling Using DNA Microarrays. Cancer Investigation, 2003, 21, 937-949.	1.3	45
44	Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Review of Endocrinology and Metabolism, 2010, 5, 753-764.	2.4	44
45	Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2017, 2017, 1-9.	3.0	42
46	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2020, 4, 1285-1301.	3.0	42
47	Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. Journal of Molecular Diagnostics, 2017, 19, 115-125.	2.8	41
48	The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer. Nature Communications, 2020, 11, 2689.	12.8	41
49	A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells. Cancer Immunology Research, 2015, 3, 1175-1184.	3.4	38
50	Targeted suppression of AR-V7 using PIP5K1Î± inhibitor overcomes enzalutamide resistance in prostate cancer cells. Oncotarget, 2016, 7, 63065-63081.	1.8	38
51	Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2016, 18, 580.	1.6	38
52	Androgen Receptor Modulation Optimized for Responseâ€"Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7â€"expressing Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 76, 843-851.	1.9	36
53	Nivolumab plus ipilimumab, with or without enzalutamide, in ARâ€V7â€expressing metastatic castrationâ€resistant prostate cancer: A phaseâ€2 nonrandomized clinical trial. Prostate, 2021, 81, 326-338.	2.3	35
54	Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Clinical Cancer Research, 2016, 22, 4651-4663.	7.0	34

#	Article	IF	Citations
55	Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. Prostate Cancer and Prostatic Diseases, 2020, 23, 381-397.	3.9	34
56	An Immune-Inflammation Gene Expression Signature in Prostate Tumors of Smokers. Cancer Research, 2016, 76, 1055-1065.	0.9	31
57	Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. Prostate, 2016, 76, 1484-1490.	2.3	29
58	Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. European Journal of Cancer, 2021, 144, 302-309.	2.8	29
59	Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. European Urology Oncology, 2018, 1, 151-159.	5.4	28
60	Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer. Translational Oncology, 2021, 14, 100915.	3.7	27
61	AR Splicing Variants and Resistance to AR Targeting Agents. Cancers, 2021, 13, 2563.	3.7	27
62	Effect of COVID-19 on childhood Mycoplasma pneumoniae infection in Chengdu, China. BMC Pediatrics, 2021, 21, 202.	1.7	24
63	Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5005-5005.	1.6	23
64	Androgen receptor variant-driven prostate cancer II: advances in clinical investigation. Prostate Cancer and Prostatic Diseases, 2020, 23, 367-380.	3.9	22
65	Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. JCI Insight, 2021, 6, .	5.0	22
66	Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. Journal of Urology, 2018, 199, 1494-1501.	0.4	21
67	Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clinical Cancer Research, 2021, 27, 4077-4088.	7.0	21
68	Regulation of androgen receptor variants in prostate cancer. Asian Journal of Urology, 2020, 7, 251-257.	1.2	19
69	Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5035-5035.	1.6	19
70	A pilot study of prostateâ€specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. Prostate, 2019, 79, 1597-1603.	2.3	18
71	Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. Genes Chromosomes and Cancer, 2020, 59, 225-239.	2.8	18
72	Genomeâ€wide expression analysis of recently processed formalinâ€fixed paraffin embedded human prostate tissues. Prostate, 2009, 69, 214-218.	2.3	17

#	Article	IF	Citations
73	PARP inhibition â€" not all gene mutations are created equal. Nature Reviews Urology, 2019, 16, 4-6.	3.8	17
74	AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort.. Journal of Clinical Oncology, 2016, 34, 5012-5012.	1.6	16
75	Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapyâ€"naÃ¯ve salivary duct carcinomas. Human Pathology, 2019, 84, 173-182.	2.0	15
76	Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy. Clinical Genitourinary Cancer, 2022, 20, 97-101.	1.9	14
77	Germline mutations in PPFIBP2 are associated with lethal prostate cancer. Prostate, 2018, 78, 1222-1228.	2.3	12
78	Reciprocal <scp>YAP1</scp> loss and <scp>INSM1</scp> expression in neuroendocrine prostate cancer. Journal of Pathology, 2021, 255, 425-437.	4.5	12
79	AR splice variant dimerizationâ€"clinical implications. Nature Reviews Urology, 2015, 12, 431-433.	3.8	10
80	Mitochondrial-Associated Protein LRPPRC is Related With Poor Prognosis Potentially and Exerts as an Oncogene Via Maintaining Mitochondrial Function in Pancreatic Cancer. Frontiers in Genetics, 2021, 12, 817672.	2.3	10
81	Non-invasive actionable biomarkers for metastatic prostate cancer. Asian Journal of Urology, 2016, 3, 170-176.	1.2	8
82	Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. Journal of Clinical Oncology, 2019, 37, 2184-2186.	1.6	7
83	Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic implications. Asian Journal of Urology, 2019, 6, 109-113.	1.2	7
84	Blood Based Detection of Androgen Receptor Splice Variants in Patients with Advanced Prostate Cancer. Journal of Urology, 2016, 196, 1606-1607.	0.4	5
85	Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer. Oral Oncology, 2018, 84, 134-136.	1.5	4
86	Specific Detection of Prostate Cancer Cells in Urine by RNA In Situ Hybridization. Journal of Urology, 2021, 206, 37-43.	0.4	4
87	Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data. Asian Journal of Andrology, 2012, 14, 385-392.	1.6	4
88	Delineating the Molecular Events Underlying Development of Prostate Cancer Variants with Neuroendocrine/Small Cell Carcinoma Characteristics. International Journal of Molecular Sciences, 2021, 22, 12742.	4.1	4
89	CDK12 Mutation in Advanced Prostate Cancer: A Marker for Clinical Subtype?. European Urology, 2020, 77, 342-343.	1.9	3
90	Predictive Biomarkers in Prostate Cancer: Is It Time To Go â€œAll Inâ€•on Liquid Biopsies?. European Urology, 2020, 78, 181-183.	1.9	3

#	Article	IF	Citations
91	A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization. Prostate Cancer and Prostatic Diseases, 2021, 24, 220-232.	3.9	3
92	Clonal hematopoiesis in prostate cancer inferred from somatic tumor profiling.. Journal of Clinical Oncology, 2021, 39, e17001-e17001.	1.6	2
93	The Expression Signature of Androgen Receptor Splice Variants and Their Distinctive Transcriptional Activities in Castration-Resistant Prostate Cancer. , 2013, , 201-213.		2
94	Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149â€“56. AR-V7 Testing: What's in it for the Patient?. European Urology, 2017, 72, e170-e171.	1.9	1
95	A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. , 2011, 71, 1656.		1
96	Marrow Stromal Cells as Universal Donor Cells for Cardiac Regenerative Therapy: Fact or Fancy?. , 2008, , 117-137.		1
97	Clinical utility of CLIA-grade AR-V7 testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 183-183.	1.6	1
98	Explaining hormone-deprivation therapy failure in prostate cancer patients. Expert Review of Endocrinology and Metabolism, 2009, 4, 103-105.	2.4	0
99	Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2021, 39, 157-157.	1.6	0
100	Use of Expression Microarrays in Cancer Research. , 2010, , 67-85.		0
101	Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide.. Journal of Clinical Oncology, 2018, 36, 221-221.	1.6	0
102	Clinical utility of androgen-receptor splice variant 7 (AR-V7) determinations in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, e17067-e17067.	1.6	0
103	Prevalence of residual tumor in the prostate after contemporary systemic therapy.. Journal of Clinical Oncology, 2018, 36, e17001-e17001.	1.6	0
104	The prognostic and predictive value of AR-V7 quantification in mCRPC.. Journal of Clinical Oncology, 2018, 36, 12026-12026.	1.6	0
105	Germline BRCA2, ATM and CHEK2 alterations shape somatic mutation landscapes in prostate cancer.. Journal of Clinical Oncology, 2022, 40, 148-148.	1.6	0